Nippon Chemiphar Co., Ltd. (4539.T) Stock

4539.T logo

Nippon Chemiphar Co., Ltd.

4539.TJapan
Healthcare

Company profile

Nippon Chemiphar reported revenue of 32.57 billion JPY for fiscal year 2025, up 5.9% from fiscal year 2024. Its largest business segment, Pharmaceutical Business, brought in 96% of segment revenue in fiscal year 2025. Our analysis of its filings shows revenue growing from 31.56 billion JPY in fiscal year 2023 to 32.57 billion JPY in fiscal year 2025, 1.6% a year on average. Nippon Chemiphar reports about 878 full-time employees.

What stands out

  • It returned to a profit in fiscal year 2025, 294.00 million JPY, after a net loss of 180.00 million JPY in fiscal year 2024.
  • Revenue in fiscal year 2025 was the highest of the last 5 fiscal years.

Figures from company filings; latest fiscal year ended March 31, 2025.

About Nippon Chemiphar Co., Ltd.

Nippon Chemiphar Co., Ltd., together with its subsidiaries, engages in the manufacture, sale, import, and export of ethical pharmaceuticals and diagnostic agents in Japan and internationally. the company offers diagnostic products, such as IgE NC, a diagnostic kit that provides results and reveals total IgE levels, as well as 57 individual allergen reagents; and DP3000, a device for allergen-specific IgE measurements. It also develops NC-2400, a PPAR-delta agonist currently under phase 1 development; NC-2500, a XOR inhibitor for the treatment of hyperuricemia/gout currently under phase 1 development; and NC-2600, a P2X4 receptor antagonist for the treatment of neuropathic pain currently under phase 1 development. In addition, the company develops NC-2700, a URAT1 inhibitor for hyperuricemia, guot currently under preclinical development; NC-2800, a delta opioid receptor agonist for the treatment of depression/anxiety currently under Phase 1 development; DFP-17729, a cancer microenvironment improving agent far pancreatic cancer currently under phase 2 development; and DE-P-14323, an anti-cancer agent for non-small cell lung cancer currently under phase 2 development. Further, it is involved in the development of generic drugs; diagnostics; new drugs; and healthcare-related products. Additionally, the company provides quasi-drugs, nutrients, health foods, cosmetics, and various types of creams. The company was formerly known as Hitachi Chemical Co., Ltd. and changed its name to Nippon Chemiphar Co., Ltd. in 1970. Nippon Chemiphar Co., Ltd. was incorporated in 1950 and is headquartered in Tokyo, Japan.

Largest shareholders

  • Nippon Chemiphar Co., Ltd.14.32%
  • Yamaguchi Family9.721 %9.72%
  • Yamaguchi Memorial Science Foundation7.04%
  • Toshima Yakuhin KK5.68%
  • Kazushiro Yamaguchi5.055 %5.05%

Share of the company, as of May 18, 2026

Leadership

  • Kazushiro Yamaguchi — Chairman, CEO & President, 67
  • Masahide Yasumoto — Ops., Info. Sys. Dept., Pub. Rel., Lab. Drugs, Corp. Plan., Mgr., Sr. Managing Corp. Offr.& Dir., 58
  • Shinji Nakajima — Corp. Officer, GM of Group Purchasing & Sales Mgmt. Center, Administration Dept. Manager & Director, 63
  • Hirofumi Miyata — Corporate Officer & GM of Human Resources
  • Kouki Hayamizu — Executive Officer, Head of Development Planning & Director, 63

How much revenue does Nippon Chemiphar make?

Nippon Chemiphar reported 32.57 billion JPY in revenue for fiscal year 2025, up 5.9% from 30.75 billion JPY in fiscal year 2024.

What is Nippon Chemiphar's largest business segment?

Pharmaceutical Business, with 31.39 billion JPY or 96% of segment revenue in fiscal year 2025. Next: Others (4%).

What companies are similar to Nippon Chemiphar?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Fuji Pharma Co., Ltd. (4554.T), StemRIM (4599.T), Solasia Pharma K.k. (4597.T).

Has Nippon Chemiphar made a profit in recent years?

Net income by fiscal year: FY2021, 495.00 million JPY; FY2022, 700.00 million JPY; FY2023, 339.00 million JPY; FY2024, a loss of 180.00 million JPY; FY2025, 294.00 million JPY. It reported a net loss in 1 of these 5 years.

How has Nippon Chemiphar's revenue changed over the last 5 fiscal years?

Revenue by fiscal year: FY2021, 31.54 billion JPY; FY2022, 32.51 billion JPY; FY2023, 31.56 billion JPY; FY2024, 30.75 billion JPY; FY2025, 32.57 billion JPY.

Company Information

SectorHealthcare
IndustryMulti-Therapeutic Drug Manufacturing
Employees878
FoundedJun 16, 1950
IPO DateOct 1, 1971
IPO StatusPublic
HeadquartersTokyo, Japan
ExchangeTokyo
TimezoneAsia/Tokyo (JST)

Contact & Links

Address
2-2-3, Iwamoto-cho, Tokyo, 101-0032
Phone
81 3 3863 1211
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “Nippon Chemiphar Co., Ltd. (4539.T)”, data as of May 18, 2026, https://dataporium.tech/stocks/4539.T

LinkedInLinkedInXXYouTubeYouTube